Avalon GloboCare Corp. ( OTCQB : AVCO ) is a global intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehabilitation."

In addition, AVCO provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. AVCO, via its subsidiary “Avalon RT9 Properties, LLC”, also engages in the acquirement and management of healthcare facility.

Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.